KLBF 2Q20 earnings exceeded our expectations, with the modest growth in distribution and consumer health segment, but weighed down by prescription drugs and nutrition segment. We also see the new catalyst which is vaccine development will have a double edged sword effect on KLBF. Meanwhile, we expect a better second half of 2020 both revenue and earnings, thus we maintain our Buy recommendation.
Download full report HERE.
